Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc [Yahoo! Finance]